Events
The Future of Clinical Proteomics: New and Emerging Innovations in Next Generation Proteomics
Organizer: The seminar is organized by the Meilahti Clinical Proteomics Unit and the National Proteomics Consortium hosted by Biocenter Finland (BF).
Target group: The seminar is targeted to scientists, clinicians, graduate and post-graduate students, and other personnel. Students need to register to get credits for their presence.
Aim of the seminar:
It has become obvious in the recent years that new technologies are needed for several special and basic proteomics applications to overcome the limitations of the mass spectrometry-based classical proteomics technologies. Since the first publication of the partial human genome in 2000/2001, proteomics has desperately tried to answer the next big challenge and Biotech’s next mantra to reveal the human proteome, without great success. Large clinical cohorts have rarely been studied on the protein level in deep detail by any available mass spectrometry-based technology. MS instruments are slow and do not have the capability to be run in parallel for hundreds of samples simultaneously. Moreover, the high dynamic range of proteins in samples usually stored in any biobank (blood, CSF and other body fluids) give a MS instrument hard time to succeed. Therefore, several new technologies have arisen and are continuously developed to set a completely new level on modern clinical proteomics. Such technologies are often usable to biobank samples directly and they also show the capacity for high-throughput and speed, making them suitable for large scale patient sample cohorts. Another challenge for MS based proteomics is the determination of stoichiometries between different proteins or post-translational modifications of a protein. Alternative peptide sequencing technologies, such as fluorosequencing, are being developed to address these needs. At the same time, mass spectrometry field is far from stagnant. The instruments are becoming faster and more sensitive, and new sample preparation techniques address some of the shortcomings of MS-based analysis. The aim of this seminar is to give the listeners a glimpse of such new technologies and to provide a good summary and comparison on the use of the two top MS instruments of today (Thermo Fisher Scientific and Bruker Corporation) for clinical sample analyses.
Registration: by 23.4.24 https://elomake.helsinki.fi/lomakkeet/129499/lomakkeet.html
Program:
09:00 – 09:10 Introduction and Welcome, Marc Baumann, Director, Meilahti Clinical Proteomics Core Facility, University of Helsinki
09:10 – 09:50 “Deep, unbiased proteomics at scale” Dr. Markus Vossmann, Vice President & General Manager EMEA and APAC, SEER, Inc.
09:55 – 10:35 “Enhance proteomics with next generation protein sequencing technology from Quantum-Si”, Richard Broadhead, Senior Field Application Scientist, Quantum-Si
10:35 – 11:00 Coffee break
11:00 – 11:40 "Shaping the Future of Healthcare: The Impact of High-Throughput Proteomics", Dr. Huthayfa Mujahed, Field Application Scientist, Olink Proteomics
11:45 – 12:30 “From Early Discovery to Clinical Trials - advancing each stage with high-plex SomaScan® proteomics”, Dr. Gary Prescott, Field Applications Scientist, Somalogic
12:30 – 13:30 Lunch
13:30 – 14:10 “Proteomics at the Crossroads: Balancing Throughput and Depth for Biomarker Discovery”, Dr. Julia Kraegenbring, Senior Application Scientist, Thermo Fisher Scientific
14:15 – 14:55 “MALDI Imaging of intact protein + Multiomics analysis from a single glass slide”, Dr. Michele Genangeli, Commercial Manager, Bruker (Remote)
15:00 – 15:30 Coffee break
15:30 – 16:10 "Robust and scalable single-molecule protein sequencing with fluorosequencing", Dr. Jagannath Swaminathan, Chief Technology Officer, Erisyon (Remote)
16:15 – 16:55 “Expanding Proteomic Horizons with Single-Molecule Proteome and Proteoform Analysis”, Parag Mallick, Founder & Chief Scientist, Nautilus Biotechnology. (Remote)
17:00 Closing remarks, Marc Baumann, Director, Meilahti Clinical Proteomics Core Facility, University of Helsinki
Research to Business funding info session
During the event you:
- will get information about the key aspects of Research to Business funding,
- learn how Helsinki Innovation Services Ltd coordinates and supports the application process of University of Helsinki applicants,
- will get an idea of the timeline and different stages of a typical Research to Business project,
- will learn about the benefits of commercialising research, from applying for Research to Business funding to setting up a company,
- can ask questions.
The event is open to all researchers and staff from all scientific fields of the University of Helsinki.
ONCOSYS Special seminar
Recent publications:
Myers et al. HATCHet2: clone- and haplotype-specific copy number inference from bulk tumor sequencing data. Preprint 2023.
Frankell et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 2023.
Grigoriadis et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Nature Protocols 2023.
Zaccaria & Raphael. Accurate quantification of copy-number aberrations and whole-genome duplications in multi-sample tumor sequencing data. Nature Communications 2020.
Pich et al. The translational challenges of precision oncology. Cancer Cell 2022.
Dissertation: Karoliina Kotaniemi
Opponent: docent Olli Teronen, University of Tampere
Dissertation: Sebastian Stenman
Opponent: Affiliated Professor Catarina Eloy, Porto University